Overcoming Workplace Disability in IBD Patients: An Observational Study.
Crohn's disease
Employment
Inflammatory bowel disease
Ulcerative colitis
Workplace disability
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
18
10
2019
accepted:
21
02
2020
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
ppublish
Résumé
Inflammatory Bowel Disease (IBD) can have considerable effects on employment outcomes because of its disabling character. We aimed to investigate the impact of IBD in the workplace and to better understand the need for accommodations and adaptations. Between November 2017 and March 2018, IBD patients were recruited from outpatient clinics in Christchurch Hospital, New Zealand. The survey assessed employment, the need for workplace accommodations and the difficulty arranging it, insurance, and disability using the item-reduced Inflammatory Bowel Disease Disability Index for self-report (IBD-DI-SR). Data were analyzed using descriptive statistics and multivariate logistic regression modeling. One hundred twenty-three patients were included (response rate 64%), 112 of whom reported that they experienced symptoms while working (60% female, 71% Crohn's disease, mean age 41.9 years). Ninety-one percent needed at least 1 workplace accommodation when symptoms were most severe. Almost half of the patients who needed an accommodation had difficulty arranging it. The most needed accommodations were time to go to medical appointments (71%) and easy access to a suitable toilet (71%). Being female, having less effective medication, and being distressed were associated with the need for 2 or more accommodations, difficulty in arranging accommodations, and not asking for needed accommodation. Many IBD patients need accommodations at work while symptomatic in order to overcome workplace disability, which can be difficult to arrange. Improved resources are needed to inform employees and employers about the disease, the possibilities for workplace accommodations, and practical strategies to request them.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammatory Bowel Disease (IBD) can have considerable effects on employment outcomes because of its disabling character.
GOALS
OBJECTIVE
We aimed to investigate the impact of IBD in the workplace and to better understand the need for accommodations and adaptations.
STUDY
METHODS
Between November 2017 and March 2018, IBD patients were recruited from outpatient clinics in Christchurch Hospital, New Zealand. The survey assessed employment, the need for workplace accommodations and the difficulty arranging it, insurance, and disability using the item-reduced Inflammatory Bowel Disease Disability Index for self-report (IBD-DI-SR). Data were analyzed using descriptive statistics and multivariate logistic regression modeling.
RESULTS
RESULTS
One hundred twenty-three patients were included (response rate 64%), 112 of whom reported that they experienced symptoms while working (60% female, 71% Crohn's disease, mean age 41.9 years). Ninety-one percent needed at least 1 workplace accommodation when symptoms were most severe. Almost half of the patients who needed an accommodation had difficulty arranging it. The most needed accommodations were time to go to medical appointments (71%) and easy access to a suitable toilet (71%). Being female, having less effective medication, and being distressed were associated with the need for 2 or more accommodations, difficulty in arranging accommodations, and not asking for needed accommodation.
CONCLUSIONS
CONCLUSIONS
Many IBD patients need accommodations at work while symptomatic in order to overcome workplace disability, which can be difficult to arrange. Improved resources are needed to inform employees and employers about the disease, the possibilities for workplace accommodations, and practical strategies to request them.
Identifiants
pubmed: 32596259
doi: 10.1159/000506702
pii: iid-0005-0084
pmc: PMC7315202
doi:
Types de publication
Journal Article
Langues
eng
Pagination
84-92Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Dr. Bernstein is supported in part by the Bingham Chair in Gastroenterology. He serves on advisory boards for Abbvie Canada, Janssen Canada, Shire Canada, Takeda Canada, Pfizer, and Ferring Canada and has consulted to Mylan Pharmaceuticals and 4-D Pharma. He has received educational grants from Abbvie Canada, Pfizer Canada, Shire Canada, Takeda Canada, and Janssen Canada and is on the speaker's panel for Ferring Canada and Shire Canada. For the remaining authors no conflict of interests exists.
Références
Gut. 2017 Apr;66(4):588-596
pubmed: 26646934
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1589-1595.e4
pubmed: 28603056
Arch Gen Psychiatry. 2003 Feb;60(2):184-9
pubmed: 12578436
Inflamm Bowel Dis. 2015 Jul;21(7):1623-30
pubmed: 26070004
Inflamm Bowel Dis. 2016 Sep;22(9):2238-44
pubmed: 27482976
J Crohns Colitis. 2014 Oct;8(10):1237-45
pubmed: 24662396
J Gastroenterol Hepatol. 2019 Jan;34(1):92-102
pubmed: 30276858
Can J Gastroenterol. 2011 Sep;25(9):492-6
pubmed: 21912760
Gastroenterology. 2013 Mar;144(3):536-43
pubmed: 23232295
J Crohns Colitis. 2014 Nov;8(11):1362-77
pubmed: 25001582
Clin Gastroenterol Hepatol. 2017 Apr;15(4):518-524
pubmed: 27717842
Inflamm Bowel Dis. 2016 Jul;22(7):1688-97
pubmed: 27271487
Inflamm Intest Dis. 2019 Feb;3(3):138-144
pubmed: 30820435
J Appl Psychol. 2017 Dec;102(12):1601-1635
pubmed: 28749157